BioSpace News Archive

BioMidwest

Spectrum Pharmaceuticals Presents Late Breaker Oral Presentation of Poziotinib Data in First-Line NSCLC Patients with HER2 Exon 20 Insertion Mutations at ESMO Congress 2021

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company focused on novel and targeted oncology therapies, announced the presentation of safety and efficacy results from Cohort 4 of the ZENITH20 clinical trial.

September 18, 2021
·
7 min read
BioCapital

ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease progression or death by 72% vs. trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer

Detailed positive results from the head-to-head DESTINY-Breast03 Phase III trial showed that ENHERTU®, the AstraZeneca and Daiichi Sankyo Company, Limited HER2-directed antibody drug conjugate, demonstrated superior progression-free survival versus trastuzumab emtansine, a HER2-directed ADC currently approved to treat patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane.

September 18, 2021
·
26 min read